Electrophysiology and Arrhythmia
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
Japan. Heart Rhythm 2013;10:533–9. https://doi.org/10.1016/j. hrthm.2012.12.023; PMID: 23274366. Kawata H, Morita H, Yamada Y, et al. Prognostic significance of early repolarization in inferolateral leads in Brugada patients with documented ventricular fibrillation: A novel risk factor for Brugada syndrome with ventricular fibrillation. Heart Rhythm 2013;10:1161–8. https://doi.org/10.1016/j. hrthm.2013.04.009; PMID: 23587501. Francis J, Antzelevitch C. Atrial fibrillation and Brugada syndrome. J Am Coll Cardiol 2008;51:1149–53. https://doi. org/10.1016/j.jacc.2007.10.062; PMID: 18355651. Morita H, Kusano-Fukushima K, Nagase S, et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol 2002;40:1437–44. https://doi. org/10.1016/S0735-1097(02)02167-8; PMID: 12392834. Brugada P, Brugada R, Mont L, et al. Natural history of Brugada syndrome. J Cardiovasc Electrophysiol 2003;14:455–7. https://doi.org/10.1046/j.1540-8167.2003.02517.x; PMID: 12776858. Fauchier L, Isorni MA, Clementy N, et al. Prognostic value of programmed ventricular stimulation in Brugada syndrome according to clinical presentation: An updated meta-analysis of worldwide published data. Int J Cardiol 2013;168:3027–9. https://doi.org/10.1016/j.ijcard.2013.04.146; PMID: 23642819. Delise P, Allocca G, Marras E, et al. Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. Eur Heart J 2011;32:169–76. https://doi.org/10.1093/eurheartj/ehq381; PMID: 20978016. Makimoto H, Kamakura S, Aihara N, et al. Clinical impact of the number of extrastimuli in programmed electrical stimulation in patients with Brugada type 1 electrocardiogram. Heart Rhythm 2012;9:242–8. https://doi. org/10.1016/j.hrthm.2011.09.053; PMID: 21939629. Sieira J, Conte G, Ciconte G, et al. Prognostic value of programmed electrical stimulation in Brugada syndrome. CircArrhythm Electrophysiol 2015;8:777–84. https://doi. org/10.1161/CIRCEP.114.002647; PMID: 25904495. Yuan M, Tian C, Li X, et al. gender differences in prognosis and risk stratification of Brugada syndrome: a pooled analysis of 4,140 patients from 24 clinical trials. Front Physiol 2018;9:1127. https://doi.org/10.3389/fphys.2018.01127; PMID:30246798. Benito B, Sarkozy A, Mont L, et al. Gender differences in clinical manifestations of Brugada syndrome. J Am Coll Cardiol 2008;52:1567–73. https://doi.org/10.1016/j.jacc.2008.07.052; PMID: 19007594. Sieira J, Conte G, Ciconte G, et al. Clinical characterisation and long-term prognosis of women with Brugada syndrome. Heart 2016;102:452. https://doi.org/10.1136/heartjnl-2015-308556; PMID: 26740482. Berthome P, Tixier R, Briand J, et al. Clinical presentation and follow-up of women affected by Brugada syndrome. Heart Rhythm 2019;16:260–7. https://doi.org/10.1016/j. hrthm.2018.08.032; PMID: 30193851. Probst V, Denjoy I, Meregalli PG, et al. Clinical aspects and prognosis of Brugada syndrome in children. Circulation 2007;115:2042–8. https://doi.org/10.1161/ CIRCULATIONAHA.106.664219; PMID: 17404158. Michowitz Y, Milman A, Andorin A, et al. Characterization and management of arrhythmic events in young patients with Brugada syndrome. J Am Coll Cardiol 2019;73:1756. https://doi. org/10.1016/j.jacc.2019.01.048; PMID: 30975291. Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of mutations in the SCN5A-encoded cardiac
174
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 2010;7:33–46. https://doi. org/10.1016/j.hrthm.2009.09.069; PMID: 20129283. Hosseini SM, Kim R, Udupa S, et al. Reappraisal of reported genes for sudden arrhythmic death. Circulation 2018;138:1195– 205. https://doi.org/10.1161/CIRCULATIONAHA.118.035070; PMID: 29959160. Yamagata K, Horie M, Aiba T, et al. Genotype-phenotype correlation of scn5a mutation for the clinical and electrocardiographic characteristics of probands with Brugada syndrome. Circulation 2017;135:2255–70. https://doi. org/10.1161/CIRCULATIONAHA.117.027983; PMID: 28341781. BrugadaDrugs.org Advisory Board. Drugs to be avoided by Brugada syndrome patients. Available at: https://www. brugadadrugs.org/avoid/ (accessed 10 August 2019). Argenziano M, Antzelevitch C. Recent advances in the treatment of Brugada syndrome. Exp Rev Cardiovasc Therap 2018;16:387–40. https://doi.org/10.1080/14779072.2018.1475 230; PMID: 29757020. Brodie OT, Michowitz Y, Belhassen B. Pharmacological therapy in Brugada syndrome. Arrhythm Electrophysiol Rev 2018;7:135–42. https://doi.org/10.15420/aer.2018.21.2; PMID: 29967687. Anguera I, García-Alberola A, Dallaglio P, et al. Shock reduction with long-term quinidine in patients with Brugada syndrome and malignant ventricular arrhythmia episodes. J Am Coll Cardiol 2016;67:1653–4. https://doi.org/10.1016/j. jacc.2016.01.042; PMID: 27150692. Belhassen B, Rahkovich M, Michowitz Y, et al. Management of Brugada syndrome: thirty-three-year experience using electrophysiologically guided therapy with class 1A antiarrhythmic drugs. Circ Arrhythm Electrophysiol 2015;8:1393– 402. https://doi.org/10.1161/CIRCEP.115.003109; PMID: 26354972. Bouzeman A, Traulle S, Messali A, et al. Long-term follow-up of asymptomatic Brugada patients with inducible ventricular fibrillation under hydroquinidine. Europace 2014;16:572–7. https://doi.org/10.1093/europace/eut279; PMID: 24068450. Hermida JS, Denjoy I, Clerc J, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol2004 May 19;43:1853–60. https://doi.org/10.1016/j.jacc.2003.12.046; PMID: 15145111. Andorin A, Gourraud JB, Mansourati J, et al. The QUIDAM study: hydroquinidine therapy for the management of Brugada syndrome patients at high arrhythmic risk. Heart Rhythm 2017;14:1147–54. https://doi.org/10.1016/j. hrthm.2017.04.019; PMID: 28411139. Márquez MF, Bonny A, Hernández-Castillo E, et al. Longterm efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review. Heart Rhythm 2012;9:1995–2000. https://doi.org/10.1016/j. hrthm.2012.08.027; PMID: 23059185. Hasegawa K, Ashihara T, Kimura H, et al. Long-term pharmacological therapy of Brugada syndrome: is J-wave attenuation a marker of drug efficacy? Int Med 2014;53:1523–6. https://doi.org/10.2169/internalmedicine.53.1829; PMID: 25030565. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004;110:1731–7. https://doi.org/10.1161/01.CIR.0000143159.30585.90; PMID: 15381640. Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 2011;123:1270–
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
9. https://doi.org/10.1161/CIRCULATIONAHA.110.972612; PMID: 21403098. Brugada J, Pappone C, Berruezo A, et al. Brugada syndrome phenotype elimination by epicardial substrate ablation. Circ Arrhythm Electrophysiol 2015;8:1373–81. https://doi.org/10.1161/ CIRCEP.115.003220; PMID: 26291334. Pappone C, Brugada J, Vicedomini G, et al. Electrical substrate elimination in 135 consecutive patients with Brugada syndrome. Circ Arrhythm Electrophysiol 2017;10:e005053. https:// doi.org/10.1161/CIRCEP.117.005053; PMID: 28500178. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2015;36:2793–867. https://doi.org/10.1093/eurheartj/ ehv316; PMID: 26320108. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001;12:268– 72. https://doi.org/10.1046/j.1540-8167.2001.00268.x; PMID: 11232628. Yan GX, Antzelevitch C. Cellular basis for the Brugada Syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999;100:1660–6.https://doi.org/10.1161/01.CIR.100.15.1660; PMID: 10517739. Antzelevitch C, Yan GX, Shimizu W. Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome. J Electrocardiol 1999;32(Suppl 1):158–65. https://doi.org/10.1016/S0022-0736(99)90074-2; PMID: 10688320. Meregalli PG, Wilde AAM, Tan HL. Pathophysiological mechanisms of Brugada syndrome: Depolarization disorder, repolarization disorder, or more? Cardiovasc Res 2005;67:367– 78. https://doi.org/10.1016/j.cardiores.2005.03.005; PMID: 15913579. Tukkie R, Sogaard P, Vleugels J, et al. Delay in right ventricular activation contributes to Brugada syndrome. Circulation 2004;109:1272–7. https://doi.org/10.1161/01. CIR.0000118467.53182.D1; PMID: 14993143. Nagase S, Kusano KF, Morita H, et al. Epicardial electrogram of the right ventricular outflow tract in patients with the Brugada syndrome: Using the epicardial lead. J Am Coll Cardiol 2002;39:1992–5. https://doi.org/10.1016/S07351097(02)01888-0; PMID: 12084598. Izumida N, Asano Y, Doi S, et al. Changes in body surface potential distributions induced by isoproterenol and Na channel blockers in patients with the Brugada syndrome. Int J Cardiol 2004;95:261–8. https://doi.org/10.1016/j. ijcard.2003.05.025; PMID: 15193830. Pieroni M, Notarstefano P, Oliva A, et al. Electroanatomic and pathologic right ventricular outflow tract abnormalities in patients with Brugada syndrome. J Am Coll Cardiol 2018;72:2747–57. https://doi.org/10.1016/j.jacc.2018.09.037; PMID: 30497561. Nademanee K, Raju H, de Noronha SV, et al. Fibrosis, connexin-43, and conduction abnormalities in the Brugada syndrome. J Am Coll Cardiol 2015;66:1976–86. https://doi. org/10.1016/j.jacc.2015.08.862; PMID: 26516000. Moncayo-Arlandi J, Brugada R. Unmasking the molecular link between arrhythmogenic cardiomyopathy and Brugada syndrome. Nat Rev Cardiol 2017;14:744. https://doi.org/10.1038/ nrcardio.2017.103; PMID: 28703223. Agullo-Pascual E, Cerrone M, Delmar M. Arrhythmogenic cardiomyopathy and Brugada syndrome: diseases of the connexome. FEBS Lett 2014;588:1322–30. https://doi. org/10.1016/j.febslet.2014.02.008; PMID: 24548564.
EUROPEAN CARDIOLOGY REVIEW